Pureos Bioventures to raise new fund in 2022
Pureos Bioventures, a Swiss VC investing in pre-clinical and clinical-stage drug developers, plans to raise a second fund of approximately CHF 250m-300m by the end of next year, managing partner Martin Münchbach told Unquote.
More on Funds
Cornerstone VC holds GBP 20m first close for debut fund
Investments will target UK tech-enabled businesses at pre-seed and seed stage led by diverse teams
Castik Capital gears up for third fund
European mid-market GP held a final close for its predecessor vehicle on EUR 1.25bn in 2019
ICG closes European Corporate fund on EUR 8.1bn
Fundraising exceeds EUR 7bn target set for eight vintage of flagship debt fund
McWin closes EUR 500m restaurant fund backed by ADIA
Food specialist also set to start fundraising for EUR 250m food tech vehicle next month
Latest News
Tikehau-backed Aerofondo set for first acquisition
Spanish aerospace-focused fund has agreed to buy precision machining company Acatec
Foreign GPs step up for large Italian deals – panel
Interest from international players is growing across a variety of sectors, but political uncertainty looms
Literacy acquires fragrance products maker Ashleigh & Burwood
Deal marks the fourth platform investment completed since the fund listing in the LSE last year
IK Partners readies Nomios for upcoming sale process
Bank of America will advise on the auction for the Dutch IT services group, formerly known as Infradata